Omar A Nassif is a registered Canadian and US patent agent who joined the firm as a partner in 2018 and has almost 30 years’ experience in patent matters.
Mr Nassif has extensive experience drafting and prosecuting patent applications, both domestically and in foreign jurisdictions. Clients regularly call on him to draft, manage and coordinate their international patent portfolios and provide strategy advice on high-value assets within their patent estates. He has patent prosecution experience in the areas of water treatment, agriculture, biomedical devices, pharmaceuticals, urethane chemistry, monoclonal antibodies, fertilisers and industrial tailings treatment processes.
Mr Nassif also has significant experience in freedom-to-operate and validity opinions, IP aspects of major business transactions (eg, the underwriting of technology-based companies), providing support in the negotiation and drafting of IP licences and providing technical support in a variety of patent litigation matters, including working with expert witnesses and inventors to draft evidence in patent litigation proceedings. He is particularly adept at transforming complicated technical documents into ones that judges and juries can easily read and understand.
The IAM Patent 1000 has recognised Mr Nassif since 2013 and has described him as a “pharmaceuticals expert” who “manages portfolios skilfully and provides crucial technical support during big-ticket trials”.
According to Who’s Who Legal, he is “genuinely one of the best around for life sciences applications” and “[w]ith ‘extensive experience’ drafting and prosecuting patent applications, clients say his ‘broad knowledge and high level of skill make him an asset’ to any firm”.
In 2015 Mr Nassif was recognised by the Legal Media Group (LMG) as its Life Sciences Canadian Patent Non-contentious Attorney of the Year. He is responsible for managing Purdue Pharma’s Canadian patent estate, which the LMG named its Canadian IP Non-contentious Impact Case of the Year for 2015.
Register for more free content
- Read more IAM blogs and articles
- Receive the editor's weekly review by email